Chris Nolet Buys Shares of AVBP
Chris Nolet increased his holdings in AVBP with a purchase of 13,562 shares.
Key Points
- Chris Nolet purchased 13,562 shares of AVBP on June 18, 2026, adding to insider activity in the company.
- Shares of AVBP traded near $31.74 on Tuesday, with several institutional investors adjusting their positions.
- Analysts from firms like Truist Securities and Citigroup maintain a buy rating on AVBP, with targets up to $50.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Chris Nolet, an insider at AVBP, bought 13,562 shares of the company on June 18, 2026. This move adds to the recent insider buying activity at AVBP, as several other insiders also made similar purchases on the same day.
Insider Buying and Selling at ArriVent BioPharma, Inc.
On June 18, 2026, Chris Nolet, along with Kristine Peterson, John Hohneker, and Merdad Parsey, each bought 13,562 shares of AVBP. Earlier in the year, on February 2, 2026, James Paul Kastenmayer, the General Counsel, and Winston Kung, the Chief Financial Officer, purchased 130,000 and 140,000 shares, respectively. None of these transactions were part of a pre-planned trading program.
Other Institutional Activity in AVBP
Suvretta Capital Management, LLC increased its holdings in AVBP by 295,048 shares, ending with 4,401,083 shares valued at approximately $101.53 million. Infinitum Asset Management, LLC added 25,000 shares, bringing its total to 4,148,923 shares worth about $95.72 million. FMR LLC, however, reduced its stake by 687,440 shares, leaving it with 3,016,132 shares valued at $69.58 million. BlackRock, Inc. grew its position by 157,463 shares, totaling 2,530,301 shares worth $58.37 million.
Analysts Set New Price Targets
On May 29, 2026, Truist Securities maintained its buy rating on AVBP with a price target of $45. Citigroup also maintained its buy rating with a $43 target on May 13, 2026. Earlier, on March 6, 2026, Oppenheimer reiterated its buy rating with a higher target of $50. The consensus among analysts remains positive, with a strong buy recommendation and a mean target price reflecting optimism.
Bottom Line
Insider buying at AVBP suggests confidence among the company's leadership, with several insiders increasing their holdings. Institutional investors have also adjusted their positions, reflecting varied strategies. Analysts continue to support AVBP with strong buy ratings and optimistic price targets. As always, these insights from insider transactions and analyst opinions are backward-looking and should be considered as part of a broader investment strategy.
Get ArriVent BioPharma, Inc. alerts
New 13F filings, insider trades, and analyst moves on $AVBP, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.